Compounded Semaglutide for Perimenopause: Stop the Weight Creep Early
In your 40s and suddenly gaining weight without changing anything? Welcome to perimenopause—where fluctuating hormones make your metabolism unpredictable. Highland Longevity prescribes compounded semaglutide (we do not dispense Wegovy or Ozempic) to give you control during the transition, before the metabolic slowdown becomes permanent.
Why Perimenopause Makes Weight Loss So Difficult
Fluctuating hormones create a metabolic environment that fights against your efforts.
Estrogen Roller Coaster
One month high, one month low. These estrogen swings affect appetite hormones, insulin sensitivity, and fat storage patterns—making weight management unpredictable.
Sleep Disruption
Hot flashes, night sweats, and insomnia are common in perimenopause. Poor sleep increases hunger hormones and makes weight loss significantly harder.
Stress and Cravings
Hormonal changes affect mood and stress response. Cortisol rises, cravings intensify, and stress eating becomes a genuine biological response—not a lack of willpower.
The Advantage of Early Intervention
Perimenopause typically lasts 4-10 years. During this time, many women gain 10-15 pounds that become increasingly difficult to lose. Starting compounded semaglutide during perimenopause offers a significant advantage: you can prevent weight gain from accumulating rather than trying to reverse years of metabolic changes.
Women who maintain a healthy weight through perimenopause typically have an easier transition into menopause. They have better metabolic flexibility, preserve more muscle mass, and experience fewer severe symptoms.
Compounded semaglutide stabilizes the chaos. While your hormones fluctuate, GLP-1 medication provides consistent appetite regulation and metabolic support—giving you predictable weight management during an unpredictable time.
- Prevent weight accumulation during the transition
- Consistent appetite control despite hormone swings
- Reduce insulin resistance (which worsens in perimenopause)
- Enter menopause at a healthier baseline weight
Comprehensive Care Beyond Medication
Perimenopause affects your entire system—not just your weight. At Highland Longevity, we take a comprehensive approach that addresses multiple factors contributing to perimenopausal weight gain.
- DEXA body composition tracking to monitor fat and muscle
- Hormone testing to understand your specific patterns
- Sleep and stress assessment (often overlooked factors)
- Protein and nutrition guidance for metabolism support
- Optional HRT discussion if symptoms warrant
Sleep, mood, energy, menstrual changes, and weight concerns are followed separately because improvement in one does not guarantee improvement in the others.
Don't Wait Until Menopause to Address Weight
Perimenopause can be a reasonable time to evaluate weight, sleep, activity, nutrition, symptoms, medications, and cardiometabolic risk. The timing and treatment plan should be individualized rather than based on a promised metabolic window.
— Dr. Josh Lindsley, DO, DABOM
Compounded Semaglutide for Perimenopause FAQs
No. Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Wegovy, Ozempic, or Rybelsus, which are brand-name semaglutide products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a state-licensed compounding pharmacy under physician supervision. Compounded medications are not FDA-approved.
Perimenopause typically begins in your early to mid-40s, sometimes earlier. During this phase, estrogen and progesterone levels fluctuate unpredictably. These hormonal swings affect your metabolism, appetite hormones, and where your body stores fat—even if your diet and exercise haven't changed.
Yes. Perimenopausal weight gain often happens despite maintaining previous habits. It tends to concentrate around the midsection, comes with increased cravings and hunger, and is accompanied by other symptoms like sleep disruption and mood changes that make weight management even harder.
Having menstrual periods does not by itself determine candidacy. Treatment requires review of medical history, contraindications, current medications, pregnancy potential, contraception, risks, and goals.
Semaglutide acts at GLP-1 receptors, but Highland's compounded formulation is not FDA-approved and should not be expected to treat perimenopausal symptoms. Hormone-related symptoms and weight concerns are evaluated separately, with medication choice based on the full clinical picture.
Cycle changes, hot flashes, sleep disturbance, and mood symptoms may occur during perimenopause, but other causes may need evaluation. Diagnosis is clinical; hormone testing is not routinely required to confirm perimenopause in every patient.
There is no universal deadline or guaranteed easier window. Evaluation can be useful whenever weight, symptoms, function, or cardiometabolic risk warrant attention, with options individualized to the patient.
Serving Fort Worth & Surrounding Communities
Our clinic is conveniently located in the Fort Worth Alliance area, just minutes from communities throughout the DFW metroplex.
Located at 4801 Golden Triangle Blvd Suite 121, Fort Worth, TX 76244
Take Control Before Menopause Arrives
Book a free consultation to discuss how semaglutide can help you manage weight during the perimenopausal transition—before the metabolic changes become permanent.
Compounded medication disclaimer: Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Wegovy®, Ozempic®, Rybelsus®, or any other brand-name semaglutide product manufactured by Novo Nordisk.
Compounded semaglutide is prepared by a state-licensed compounding pharmacy under the supervision of our physician. Compounded medications are not FDA-approved. They are permitted under federal law when an FDA-approved product cannot meet the patient's clinical needs, or when the FDA designates a shortage. Your physician will discuss the implications, risks, and benefits of compounded therapy at your consultation.